| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
NCT04446663: Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2a | 50 | NA | Toripalimab, JS001, Albumin-bound Paclitaxel, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT | First People's Hospital of Foshan | Nasopharyngeal Neoplasms | 12/23 | 12/24 | | |
NCT05342506: Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies |
|
|
| Not yet recruiting | 2a | 30 | NA | Toripalimab + ScTIL | Peking Union Medical College Hospital, Chineo Medicine (Beijing) Co., Ltd. | Cervical Cancer, Ovarian Cancer, Malignant Trophoblastic Tumor | 02/24 | 05/24 | | |
RC48-C024, CTR20231476: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab alone or in combination with toripalimab or sequential chemotherapy in patients with HR-negative, HER2-low breast cancer |
|
|
| Ongoing | 2 | | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, carboplatin - Generic mfg., epirubicin - Generic mfg., cyclophosphamide - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HR-negative, HER2-low breast cancer | | | | |
RC48-C026, CTR20232220: A randomized, open-label, multicenter phase II clinical study evaluating the efficacy and safety of vedicitumab versus pertuzumab with or without toripalimab in the neoadjuvant treatment of patients with HER2-positive breast cancer |
|
|
| Ongoing | 2 | 80 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, Perjeta (pertuzumab) - Roche | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-positive breast cancer | | | | |
RC48-C022, CTR20233553: A phase II clinical study to evaluate the efficacy and safety of injectable vedicitumab plus toripalimab with or without chemotherapy (capecitabine + oxaliplatin) versus chemotherapy for the perioperative treatment of resectable locally advanced gastric/g |
|
|
| Recruiting | 2 | 90 | China | Aidixi (disitamab vedotin) - Rongchang Pharma, Pfizer, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci, capecitabine - Generic mfg., oxaliplatin - Generic mfg. | Remegen Biopharmaceutical (Yantai) Co., Ltd | HER2-expressing resectable locally advanced gastric/gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2100049563: A single-arm, phase II study to toripalimab combined with pazopanib in treatment of patients with simple lung metastasis clear cell renal cell carcinoma before operation |
|
|
| Not yet recruiting | 2 | 40 | China | Toripalimab combined with pazopanib | Fudan University Shanghai Cancer Center ; Fudan University Shanghai Cancer Center, No | Clear Cell Renal Cell Carcinoma | | | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
NCT04177797: Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 20 | RoW | Toripalimab | Sichuan Cancer Hospital and Research Institute | Esophageal Squamous Cell Carcinoma | 06/20 | 12/23 | | |
NCT04605796: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 2 | 54 | RoW | Toripalimab combined with Bevacizumab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/20 | 12/22 | | |
| Active, not recruiting | 2 | 25 | RoW | Tolipalimab, JS001, Reirradiation | Sun Yat-sen University | Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm | 02/21 | 02/23 | | |
NASCR, NCT03623776: Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. |
|
|
| Active, not recruiting | 2 | 80 | RoW | JS001, Toripalimab, Pemetrexed, Pemetrexed Disodium, Carboplatin, CBP, Thoracic Surgery | Sun Yat-sen University | Efficacy and Safety | 03/21 | 03/24 | | |
NCT04170179: Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis |
|
|
| Recruiting | 2 | 25 | RoW | Systemic chemotherapy, Lenvatinib, Toripalimab | Sun Yat-sen University | Hepatocellular Carcinoma | 04/21 | 04/21 | | |
ChiCTR1900023710: Toripalimab combined with capecitabine for locally persistent nasopharyngeal carcinoma after radical chemoradiotherapy: a prospective, single-arm, phase II trial |
|
|
| Not yet recruiting | 2 | 23 | China | Toripalimab combined with capecitabine | Department of Nasopharyngeal Carcinoma, Cancer Center, Sun Yat-sen University ; Sun Yat-sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents six courses of Toripalimab for each patient. | Nasopharyngeal Carcinoma | | | | |
ChiCTR2000033668: TACE and Lenvatinib Plus PD-1 Antibody Versus TACE Plus Lenvtinib for Advanced HCC: a Single-Centre Randomised Controlled Trial |
|
|
| Not yet recruiting | 2 | 80 | China | TACE+Lenvatinib plus toripalimab, an inhibitor of PD1 ;TACE+Lenvatinib | Eastern Hepatobiliary Surgery Hospital ; Eastern Hepatobiliary Surgery Hospital, Shanghai Junshi Biopharmaceutical Technology Co., Ltd. | Advanced unresectable HCC | | | | |
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 128 | RoW | neoadjuvant treatment | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital | Cholangiocarcinoma, Intrahepatic | 08/21 | 08/23 | | |
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Bevacizumab, QL1101, Tripleitriumab, JS001 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd. | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 09/21 | 02/22 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
ChiCTR2000031730: Open-label, single-center phase II clinical trial of low-dose dicitabine combined with triplezumab for the treatment of recurrent refractory follicular lymphoma |
|
|
| Recruiting | 2 | 46 | China | low-dose dicitabine combined with triplezumab | Cancer Prevention and Treatment Center, Sun Yat-Sen University ; Cancer Prevention and Treatment Center, Sun Yat-Sen University, Unfunded projects | Follicular lymphoma | | | | |
ZLJS2019, ChiCTR1900026420: A prospective, open-labelled, phase II clinical trial of neoadjuvant JS001 for resectable non-small cell lung cancer |
|
|
| Not yet recruiting | 2 | 45 | | After 2 cycles of neoadjuvant JS001 (3mg/kg Q2W, ivdrip), all participants will undergo curative resection of lung cancer. | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Junshi Bioscieces | Non-small cell lung cancer | | | | |
ChiCTR2000029713: Albumin paclitaxel plus platinum and toripalimab as first-line treatment for recurrent/metastatic head and neck squamous cell carcinaoma: Phase II Clinical Trial |
|
|
| Not yet recruiting | 2 | 37 | China | Albumin paclitaxel plus platinum and toripalimab | Shenzhen Hospital of cancer hospital of Chinese Academy of Medical Sciences ; Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen Center, Raise independently | Head and neck squamous cell carcinaoma | | | | |
NCT03925090: Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients |
|
|
| Active, not recruiting | 2 | 150 | RoW | Cisplatin+Toripalimab, DDP+ JS001, Cisplatin+placebo, DDP | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/21 | 10/23 | | |
NCT04301557: PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | PD-1 Antibody, Toripalimab, Oxaliplatin, Capecitabine, External beam radiotherapy, Total mesorectal excision | Sun Yat-sen University | DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer | 04/24 | 12/24 | | |
ChiCTR2000029277: Neoadjuvant Toripalimab in Combination With SABR in Resectable NSCLC |
|
|
| Recruiting | 2 | 30 | China | Toripalimab +SABR | Jinling Hospital ; Jinling Hospital, No | Non small cell lung cancer | | | | |
NCT04437212: Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab, JS-001 | RenJi Hospital | Advanced Esophageal Squamous Cell Cancer | 12/21 | 12/23 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04211012: A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Toripalimab plus Nab-Paclitaxel +/- cisplatin | Jun Guo | Urothelial Carcinoma | 01/22 | 01/23 | | |
| Not yet recruiting | 2 | 15 | NA | Toripalimab, carboplatin, pemetrexed | Shanghai Pulmonary Hospital, Shanghai, China | Malignant Pleural Mesothelioma | 01/22 | 05/25 | | |
| Not yet recruiting | 2 | 15 | NA | Toripalimab, carboplatin, paclitaxel | Shanghai Pulmonary Hospital, Shanghai, China | Tracheal Squamous Cell Carcinoma | 01/22 | 05/25 | | |
ZLK-XXY-1, NCT04202484: Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules | RenJi Hospital | Gastric Cancer | 02/22 | 02/23 | | |
NCT04296747: Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer |
|
|
| Not yet recruiting | 2 | 100 | NA | induction chemotherapy, surgery, chemoradiotherapy | Peking Union Medical College Hospital | Hypopharyngeal Squamous Cell Carcinoma | 03/22 | 03/23 | | |
GLYY-EC-NAD-01, NCT04644250: Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 32 | RoW | Toripalimab, JS-001, Paclitaxel liposome/Carboplatin, PCb, Intensity-modulated radiotherapy, IMRT | Wei Ren | Esophageal Squamous Cell Carcinoma | 03/22 | 03/24 | | |
NCT04725448: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 27 | RoW | Toripalimab, JS001, Toripalimab Injection, TuoYI, Teruipuli Dankang, Bevacizumab, Bevacizumab Injection, Avastin, Bei Fa Zhu Dankang Zhusheye, Nab-paclitaxel, ABRAXANE, paclitaxel protein-bound particles for injectable suspension, Carboplatin, Carboplatin injection | Sichuan Cancer Hospital and Research Institute | Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms | 03/22 | 11/23 | | |
NCT04354662: Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab, JS001, Docetaxel, Fluorouracil, Leucovorin, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 03/22 | 06/24 | | |
NCT04316351: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Recruiting | 2 | 60 | RoW | Toripalimab + Pemetrexed + Anlotinib, JS001 | Guangzhou Institute of Respiratory Disease, Shanghai Junshi Bioscience Co., Ltd. | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy | 04/22 | 04/22 | | |
| Recruiting | 2 | 38 | RoW | niraparib combined with brivanib, Treatment group1, niraparib combined with toripalimab, Treatment group2 | Chongqing University Cancer Hospital | Cervical Cancer | 04/22 | 07/22 | | |
| Active, not recruiting | 2 | 220 | RoW | humanized anti-PD-1 monoclonal antibody Toripalimab, JS001, TAB001, high-dose recombinant interferon a-2B, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Intron A | Shanghai Junshi Bioscience Co., Ltd. | Mucosal Melanoma | 04/22 | 04/25 | | |
NCT04524884: Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study |
|
|
| Not yet recruiting | 2 | 10 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Fudan University | Thyroid Cancer | 04/22 | 09/22 | | |
ChiCTR2000031692: A prospective phase II clinical study of TACE combined with triplezumab and metronochemotherapy in the treatment of advanced hepatocellular carcinoma (HCC) |
|
|
| Not yet recruiting | 2 | 30 | China | TACE combined with triplezumab and metronochemotherapy | The Seventh Affiliated Hospital of Sun Yat-Sen University ; The Seventh Affiliated Hospital of Sun Yat-Sen University, Self-raised funds | Hepatocellular carcinoma (HCC) | | | | |
NCT04338282: Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 20 | NA | toripalimab, anti-PD-1-antibody | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma, Nasal Type | 05/22 | 05/23 | | |
NCT03941795: Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma |
|
|
| Recruiting | 2 | 99 | RoW | JS001(Toripalimab Injection), Axitinib 1 MG [Inlyta], JS001 and Axitinib | Peking University Cancer Hospital & Institute | Advanced Mucosal Melanoma | 06/22 | 12/22 | | |
ChiCTR2000033506: A phase II trial of TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy for patients with local advanced laryngeal/hypopharyngeal carcinoma |
|
|
| Recruiting | 2 | 43 | China | TP and Toripalimab neoadjuvant chemotherapy followed by Toripalimab concurrent radiotherapy | Sun Yat-Sen University Cancer Center ; Level of the institution：, Shanghai Junshi Biosciences Co., Ltd. | Laryngeal carcinoma /hypopharyngeal carcinoma | | | | |
NCT04992988: Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial |
|
|
| Recruiting | 2 | 40 | RoW | Toripalimab | Cancer Hospital of Guangxi Medical University | Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma | 06/22 | 06/22 | | |
NCT04825938: Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms |
|
|
| Not yet recruiting | 2 | 15 | RoW | Toripalimab , Carboplatin, Nab-paclitaxel | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Salivary Gland Malignant Neoplasms, Salivary Gland Tumors | 06/22 | 06/27 | | |
NCT04891016: Toripalimab Plus FLOT in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 60 | RoW | FLOT combined with toripalimab, FLOT plus toripalimab | Henan Cancer Hospital | Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma | 12/25 | 12/28 | | |
MTAM, NCT04472806: Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma |
|
|
| Recruiting | 2 | 31 | RoW | Toripalimab, JS001, chemotherapy in combination with Endostar | Fudan University, Zhejiang Cancer Hospital, Fujian Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Mucosal Melanoma | 06/22 | 06/23 | | |
NCT04250948: Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer |
|
|
| Active, not recruiting | 2 | 108 | RoW | JS001, PD-1 antibody, Oxaliplatin, S1, Capecitabine, XELODA | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Gastric Cancer, Locally Advanced Solid Tumor | 06/22 | 10/24 | | |
NCT06156891: PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC |
|
|
| Recruiting | 2 | 60 | RoW | Toxicities reduced treatment, Conventional treatment | Fudan University | Oropharyngeal Cancer | 07/25 | 07/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer |
|
|
| Completed | 2 | 40 | RoW | Toripalimab combination with platinum-containing dual-drug chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
ChiCTR1900022491: A phase 2 study for PD-1 antibody JS001 in Participants With Microsatellite Instability-High (MSI-H) advanced or recurrent colorectal cancer |
|
|
| Not yet recruiting | 2 | 40 | | JS001 | Fudan University Zhongshan Hospital; Fudan University Zhongshan Hospital, Shanghai Tongshu Biotech Co., Ltd；Shanghai Junshi biosciences Co., Ltd | Colorectal cancer | | | | |
ChiCTR2100043981: Toripalimab Combined with Concurrent Chemoradiotherapy in Stage IV Hypopharyngeal Carcinoma without Distant Metastasis |
|
|
| Recruiting | 2 | 76 | China | Toripalimab combined with concurrent chemotherapy ;concurrent chemotherapy | National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC ; Level of the institution：, Suzhou Zhonghe Biomedical Technology Co., Ltd | hypopharyngeal cancer | | | | |
NCT04627363: HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama |
|
|
| Not yet recruiting | 2 | 30 | NA | Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Bevacizumab, Liver Neoplasms, Toripalimab, Oxaliplatin | 06/22 | 06/23 | | |
NCT04398056: Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 22 | RoW | Chemotherapy plus radiotherapy and Toripalimab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 07/22 | 07/24 | | |
| Recruiting | 2 | 30 | RoW | TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®) | Peking University Cancer Hospital & Institute | Mucosal Melanoma | 07/22 | 12/22 | | |
NCT03946943: Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma |
|
|
| Not yet recruiting | 2 | 25 | RoW | Anlotinib, Toripalimab, Blood Draw, Phlebotomy, Tumor Specimen Collection, Core-Needle Biopsy | Di Wu | Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | 07/22 | 07/23 | | |
ChiCTR2000039371: Evaluating the efficacy and safety of Teriprizumab injection (JS001) combined with lenvatinib as first-line treatment in patients with Advanced Hepatocellular Carcinoma: a single-arm, open-label clinical trial. |
|
|
| Recruiting | 2 | 30 | China | Teriprizumab injection + Lenvatinib | Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Guangxi Medical University ; Affiliated Cancer Hospital of Guangxi Medical University, Shanghai Junshi Biomedical Technology Co., Ltd. | Hepatocellular Carcinoma | | | | |
NCT04888403: Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Toripalimab+Nedaplatin+Albumin Paclitaxel | The First Affiliated Hospital of Zhengzhou University | Locally Advanced Esophageal Squamous Cell Carcinoma | 07/22 | 07/22 | | |
| Not yet recruiting | 2 | 14 | RoW | Surufatinib(HMPL-012), Toripalimab | Fujian Cancer Hospital | Nasopharyngeal Carcinoma | 08/22 | 08/23 | | |
IMPORT, NCT04523883: Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The Study |
|
|
| Recruiting | 2 | 316 | RoW | postoperative radiotherapy, JS001, Toripalimab | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Fudan University, Eye & ENT Hospital of Fudan University, Tianjin Medical University Cancer Institute and Hospital, First Affiliated Hospital of Fujian Medical University, Guizhou Provincial People's Hospital, Central South University | Head and Neck Squamous Cell Carcinoma | 08/22 | 08/24 | | |
NCT04278222: Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE) |
|
|
| Recruiting | 2 | 30 | RoW | Anlotinib Plus Toripalimab | Shanghai Changzheng Hospital | Gastric Cancer, Gastro-oesophageal Junction Cancer, Immunotherapy, Anlotinib, Toripalimab | 08/22 | 08/22 | | |
NeoTENNIS, NCT04418154: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients |
|
|
| Active, not recruiting | 2 | 70 | RoW | epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel, Toripalimab | Fudan University | Triple Negative Breast Cancer | 09/22 | 12/25 | | |
NCT04119622: Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, oxaliplatin, capecitabine | Aiping Zhou | Gastric Cancer Stage II, Gastric Cancer Stage III | 09/22 | 10/24 | | |
NCT04099589: Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma |
|
|
| Recruiting | 2 | 64 | RoW | Toripalimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University First Hospital, China-Japan Friendship Hospital | Upper Tract Urinary Carcinoma, Muscle-invasive Bladder Cancer | 10/22 | 10/22 | | |
NCT04880811: Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification |
|
|
| Not yet recruiting | 2 | 43 | RoW | Afatinib, Toripalimab | Peking University | Esophageal Squamous Cell Carcinoma | 10/22 | 05/23 | | |
ChiCTR2000039175: Clinical Study of Toripalimab with Anlotinib for Patients With Recurrent Glioblastoma |
|
|
| Recruiting | 2 | 50 | China | Toripalimab and Anlotinib | Tangdu Hospital, Fourth Military Medical University ; Tangdu Hospital, cost of scientific research | recurrent glioblastoma | | | | |
NCT05350943: HAIC Combined With Toripalimab and Donafenib for Advanced BTC |
|
|
| Enrolling by invitation | 2 | 70 | RoW | HAIC, Gemcitabine, Oxaliplatin, Toripalimab, Donafenib | Lu Wang, MD, PhD | Biliary Tract Adenocarcinoma | 11/22 | 11/23 | | |
NCT05522985: Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 122 | RoW | Triprilimab combined with TP | Tianjin Medical University Cancer Institute and Hospital | Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy | 11/22 | 11/24 | | |
NCT04613804: Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy |
|
|
| Not yet recruiting | 2 | 30 | RoW | Toripalimab Injection, PD-1 inhibitor | Fujian Cancer Hospital | NSCLC Stage IV | 11/22 | 11/23 | | |
| Completed | 2 | 50 | RoW | GS+Toripalimab | Shanghai Zhongshan Hospital, Shanghai Junshi Bioscience Co., Ltd., OrigiMed | Biliary Tract Cancer | 12/21 | 03/22 | | |
NCT04973904: Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer |
|
|
| Not yet recruiting | 2 | 35 | RoW | Toripalimab, Paclitaxel, Cisplatin, Bevacizumab | Peking Union Medical College Hospital | Cervical Cancer | 12/22 | 12/23 | | |
NCT04443036: Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma |
|
|
| Recruiting | 2 | 44 | RoW | Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound), Toripalimab | China Medical University, China | Gastric Carcinoma | 12/22 | 12/23 | | |
| Not yet recruiting | 2 | 40 | China | 特瑞普利单抗联合全脑放疗 | Department of Radiation Oncology, Third Affiliated Hospital of Soochow University ; Third Affiliated Hospital of Soochow University, Self funding | Malignant neoplasm metastasis in brain | | | | |
NCC2167, NCT04389073: Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine |
|
|
| Recruiting | 2 | 138 | RoW | Vinorelbine 40mg, Toripalimab 240mg, JS001, Bevacizumab 5 mg/kg, Cyclophosphamide 50 mg, Capecitabine 500Mg Oral Tablet, Cisplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Huanxing Cancer Hospital | Metastatic Breast Cancer | 12/22 | 12/23 | | |
NCT04363255: First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC |
|
|
| Not yet recruiting | 2 | 20 | RoW | Etoposide Injection, Etoposide, Carboplatin Injection, Carboplatin, Cisplatin injection, Cisplatin, Toripalimab, JS001, Anlotinib hydrochloride, Anlotinib | Taizhou Hospital | Small Cell Lung Carcinoma | 12/22 | 03/23 | | |
NCT04425824: Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | Toripalimab combine with Rituximab, JS001 combine with rituxan | Chinese Academy of Medical Sciences | Diffuse Large B-cell Lymphoma, Rituximab, Toripalimab | 12/22 | 12/22 | | |
NCT04563975: Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 54 | RoW | Toripalimab, JS001, Docetaxel, Taxotere, nab-paclitaxel, AI YUE | Tao Zhang | Gastric Cancer Stage IV | 12/22 | 05/23 | | |
NCT04238169: Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC |
|
|
| Completed | 2 | 60 | RoW | Bevacizumab, Toripalimab, SBRT | Xinqiao Hospital of Chongqing | Non-Small-Cell Lung Cancer Stage IV | 12/22 | 12/23 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05084677: Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer |
|
|
| Recruiting | 2 | 96 | RoW | Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancer | 12/22 | 12/24 | | |
NCT05453383: Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib |
|
|
| Recruiting | 2 | 30 | RoW | Anlotinib;Toripalimab, AL3818;JS001 | Shen Feng | Hepatocellular Cancer | 12/22 | 12/22 | | |
ATNPC, NCT04718701: Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Anlotinib+Toripalimab+Nab-paclitaxel, combination therapy | The First Affiliated Hospital with Nanjing Medical University | Pancreatic Neoplasm, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | 02/23 | 02/23 | | |
NCT06241105: Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer |
|
|
| Recruiting | 2 | 69 | RoW | Lenvatinib+Toripalimab. | Peking Union Medical College Hospital, The Second Affiliated Hospital of Dalian Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recurrent Ovarian Carcinoma | 12/24 | 12/25 | | |
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 2 | 248 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Hutchison Medipharma Limited | Advanced Solid Tumors | 02/23 | 02/23 | | |
NCT04118855: Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma |
|
|
| Completed | 2 | 20 | RoW | Toripalimab, anti-PD-1 monoclonal antibody, Axitinib | RenJi Hospital | Neoadjuvant Therapy of Non-metastatic Locally Advanced Renal Cell Carcinoma | 02/23 | 03/23 | | |
NCT04405622: Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. |
|
|
| Active, not recruiting | 2 | 21 | RoW | Toripalimab plus gemcitabine | Sun Yat-sen University | Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy | 03/23 | 05/23 | | |
NCT05274438: Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut |
|
|
| Recruiting | 2 | 37 | RoW | JS001+Imatinib mesylate | Beijing Cancer Hospital | Advanced Melanoma | 03/23 | 04/23 | | |
NCT05147844: Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Toripalimab, JS001 | Xinqiao Hospital of Chongqing, Southwest Hospital, China, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma | 12/25 | 03/26 | | |
NCT04421469: Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC |
|
|
| Not yet recruiting | 2 | 39 | RoW | Triprilimab(JS001) | Fujian Cancer Hospital, Zhejiang Cancer Hospital, Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 04/23 | 06/23 | | |
NCT05030246: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 72 | RoW | Surufatinib/Toripalimab, HMPL-012/JS001 | Peking University | Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer | 04/23 | 07/23 | | |
NCT05003037: Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 106 | RoW | Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin | Li Zhang, MD | Carcinoma, Non-Small-Cell Lung | 04/23 | 04/25 | | |
GIHSYSU-14, NCT03926338: Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer |
|
|
| Recruiting | 2 | 112 | RoW | Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months, Toripalimab, Celecoxib, Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months, Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months, Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months | Sun Yat-sen University | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 04/27 | 04/30 | | |
NCT04553939: Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Toripalimab, Gemcitabine | Henan Cancer Hospital | Urothelial Carcinoma, Bladder Cancer | 05/23 | 12/23 | | |
NCT05448183: An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 45 | RoW | Toripalimab, Gemcitabine,Oxaliplatin | Xuhua Duan | Extrahepatic Cholangiocarcinoma | 05/23 | 05/24 | | |
NCT04217954: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC |
|
|
| Completed | 2 | 32 | RoW | OXA, 5-FU and bevacizumab plus Toripalimab, FOLFOX | Peking University | Advanced Biliary Tract Cancer | 05/23 | 06/23 | | |
Renaissance, NCT04606303: A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. |
|
|
| Enrolling by invitation | 2 | 100 | RoW | Toripalimab combination with platinum-containing dual-drug chemotherapy. | Peking University Cancer Hospital & Institute | Locally Advanced NSCLC | 05/23 | 05/24 | | |
ChiCTR2100046726: A multi-center, open-label, randomized controlled phase II clinical trial of Toripalimab combined with chemoradiotherapy in newly diagnosed locally advanced laryngopharyngeal carcinoma |
|
|
| Recruiting | 2 | 100 | China | TP (Docetaxel + Cisplatin) combined with teriprizumab induction chemotherapy ;Concurrent chemoradiation | Sichuan Cancer Hopspital/Institute ; Sichuan Cancer Hopspital/Institute, The toripalimab is provide by drug companies | laryngopharyngeal carcinoma | | | | |
ChiCTR2100046715: A single-arm, prospective, open-label, phase II clinical trial of toripalimab in combination with induction chemotherapy and concurrent chemoradiation as first-line treatment for advanced/metastatic esophageal carcinoma |
|
|
| Recruiting | 2 | 30 | China | toripalimab in combination with induction chemotherapy and concurrent chemoradiation | Sichuan Cancer Hospital & Institute ; Sichuan Cancer Hospital & Institute, Shanghai Junshi Bioscience Co., Ltd. | Esophagus cancer | | | | |
ChiCTR2000039739: Phase II Study of Thermal Ablation Followed by Toripalimab in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 130 | | Toriplimab is administrated 3 mg/kg intravenously every 3 weeks continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends. ;One to three lesions were completely ablated under the guidance of CT or ultrasound, and toriplimab therapy was started on the third day after ablation (the dose was 3mg / kg, once every three weeks). | Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, Shanghai Junshi Biosciences Co., Ltd. | Hepatocellular carcinoma | | | | |
NCT05356351: An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | RC48- ADC, Triplizumab | Tianjin Medical University Cancer Institute and Hospital, Xiangya Hospital of Central South University, First Affiliated Hospital Xi'an Jiaotong University, The Southwest Hospital of AMU, Tongji Hospital, Chongqing University Cancer Hospital, Hunan Cancer Hospital, Xijing Hospital of Air Force Military Medical University | Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance | 07/23 | 07/27 | | |
NCT06354231: DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC |
|
|
| Recruiting | 2 | 20 | RoW | DV, RC48, Toripalimab, JS001, Laser surgery | Fudan University | Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney | 12/26 | 12/26 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
